RBOT vs. INGN, AVR, ZJYL, MLSS, NTRB, APT, SPAI, COCH, CLGN, and LFWD
Should you be buying Vicarious Surgical stock or one of its competitors? The main competitors of Vicarious Surgical include Inogen (INGN), Anteris Technologies Global (AVR), Jin Medical International (ZJYL), Milestone Scientific (MLSS), Nutriband (NTRB), Alpha Pro Tech (APT), Safe Pro Group Inc. Common Stock (SPAI), Envoy Medical (COCH), CollPlant Biotechnologies (CLGN), and ReWalk Robotics (LFWD). These companies are all part of the "surgical appliances & supplies" industry.
Vicarious Surgical vs.
Vicarious Surgical (NYSE:RBOT) and Inogen (NASDAQ:INGN) are both small-cap medical companies, but which is the better investment? We will compare the two businesses based on the strength of their risk, valuation, community ranking, institutional ownership, media sentiment, analyst recommendations, dividends, earnings and profitability.
Vicarious Surgical presently has a consensus price target of $9.25, suggesting a potential upside of 34.16%. Inogen has a consensus price target of $9.50, suggesting a potential upside of 40.74%. Given Inogen's stronger consensus rating and higher probable upside, analysts plainly believe Inogen is more favorable than Vicarious Surgical.
Inogen received 382 more outperform votes than Vicarious Surgical when rated by MarketBeat users. Likewise, 68.78% of users gave Inogen an outperform vote while only 32.00% of users gave Vicarious Surgical an outperform vote.
Vicarious Surgical has higher earnings, but lower revenue than Inogen. Inogen is trading at a lower price-to-earnings ratio than Vicarious Surgical, indicating that it is currently the more affordable of the two stocks.
In the previous week, Inogen had 3 more articles in the media than Vicarious Surgical. MarketBeat recorded 6 mentions for Inogen and 3 mentions for Vicarious Surgical. Inogen's average media sentiment score of 0.96 beat Vicarious Surgical's score of -0.67 indicating that Inogen is being referred to more favorably in the news media.
47.3% of Vicarious Surgical shares are held by institutional investors. Comparatively, 89.9% of Inogen shares are held by institutional investors. 12.0% of Vicarious Surgical shares are held by insiders. Comparatively, 1.5% of Inogen shares are held by insiders. Strong institutional ownership is an indication that large money managers, endowments and hedge funds believe a company will outperform the market over the long term.
Vicarious Surgical has a beta of 1.46, suggesting that its stock price is 46% more volatile than the S&P 500. Comparatively, Inogen has a beta of 1.63, suggesting that its stock price is 63% more volatile than the S&P 500.
Vicarious Surgical has a net margin of 0.00% compared to Inogen's net margin of -15.89%. Inogen's return on equity of -27.38% beat Vicarious Surgical's return on equity.
Summary
Inogen beats Vicarious Surgical on 13 of the 17 factors compared between the two stocks.
Get Vicarious Surgical News Delivered to You Automatically
Sign up to receive the latest news and ratings for RBOT and its competitors with MarketBeat's FREE daily newsletter.
New MarketBeat Followers Over Time
This chart shows the number of new MarketBeat users adding {thisCompany.Symbol} and its top 5 competitors to their watchlist. Each company is represented with a line over a 90 day period.
Skip ChartMedia Sentiment Over Time
This chart shows the average media sentiment of NYSE and its competitors over the past 90 days as caculated by MarketBeat. The averaged score is equivalent to the following: Very Negative Sentiment <= -1.5, Negative Sentiment > -1.5 and <= -0.5, Neutral Sentiment > -0.5 and < 0.5, Positive Sentiment >= 0.5 and < 1.5, and Very Positive Sentiment >= 1.5.
Skip Chart
Vicarious Surgical Competitors List
Related Companies and Tools
This page (NYSE:RBOT) was last updated on 5/22/2025 by MarketBeat.com Staff